For the first time, this study identifies a multimarker prognostic signature in a multicenter, phase III trial on mRCC. A first advantage of extrapolating data from a large multicenter study, as the authors state, is that it is less vulnerable to bias introduced by the single institution procedures about tissue handling and storage. Another strong point of this study is that, while other biomarker studies also included patients with localized and non-metastatic RCC, Kim and colleagues' study includes only advanced disease, permitting a more practice clinical application in a group of patients in which RCC is associated with a bad prognosis. The methods used to identify genes, based on real-time PCR, are routinely performed by many hospitals and laboratories and they are highly reproducible and usually inexpensive in clinical practice, making the study very interesting in the identification of predicting and prognostic factors in RCC. Although Kim and colleagues' study is very extensive and well described, the main limitation is the lack of an external validation cohort.
The study is a good example of molecular research; it highlights the need for identification of prognostic factors and predictive ones and provides new molecular targets. The originality of this paper is the identification of a molecular multimarker prognostic signature in RCC, which supports the well known clinical prognostic factors.
These findings raise some points for further investigation. First, the identification of a model of genes predictive of OS in RCC, together with the best known MSKCC risk factor, could allow physicians to stratify and select patients for the best treatment strategies. These findings highlight the need for identifying new molecular predictive factors that can enhance clinical ones (which are largely available and solidly used in clinical practice). Second, it would be interesting to establish if the expression of a particular gene among those identified is a predictive factor of response or resistance to specific treatments. This will certainly guide treatment decisions. Third, methodology should be simple and standardized in order to be duplicated in a real-world unselected population. Finally, appropriately sized and rigorously evaluated prospective studies or prospectively collected external datasets would be useful to put this method and these findings into clinical practice.
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